EUVIMEDEUVIMED entdecken
Crossref

Mitigating Uricase Immunogenicity through Zwitterionic Peptide Fusion for Enhanced Gout Therapy

Zhun Bao, Qingsi Li, Zhaoyu Zhou, Jing Yang iD, Lei Zhang iD

Langmuir · 2025

DOI: 10.1021/acs.langmuir.5c00829 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Langmuir, 2025. Verfasst von Zhun Bao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China. Hauptthemen laut MEDLINE: Urate Oxidase, Gout, Peptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Haihe Laboratory of Sustainable Chemical Transformation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uricase is a promising protein drug for treating gout, but its therapeutic efficacy is significantly limited by its high immunogenicity. In this study, we successfully mitigated the immunogenicity of uricase by fusing zwitterionic peptides (repeated VPKEG sequences) with varying lengths through synthetic biology. The results show that longer zwitterionic peptides can more efficiently improve the enzymatic activity, enhance the substrate affinity, prolong the blood circulation time, and reduce the antibody response. This is likely due to the longer zwitterionic peptides providing a more extensive protective hydration layer, which can shield the immunogenic sites of uricase. As a result, U-(VPKEG) 60, the uricase with the longest zwitterionic peptide, significantly enhances therapeutic effects for rat gout models. Moreover, it also exhibits excellent biocompatibility with no hemolysis and negligible cytotoxicity to liver, heart, and kidney functions. Our findings provide new insights into the development of low-immunogenicity uricase through synthetic biology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urate OxidaseGoutPeptidesAnimalsRatsMaleHumansRats, Sprague-Dawley

Substanzen

Urate OxidasePeptides

Autor:innen und Institutionen

  • Department of Biochemical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300350, China.
  • State Key Laboratory of Synthetic Biology, Tianjin University, Tianjin 300072, China.
  • Haihe Laboratory of Sustainable Chemical Transformations, Tianjin 300192, China.
  • Department of Biological Engineering, Frontier Science Center for Synthetic Biology and Key Laboratory of Systems Bioengineering (MOE), School of Synthetic Biology and Biomanufacturing, Tianjin University, Tianjin 30035…

ORCID-Profile: Jing Yang, Lei Zhang

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Haihe Laboratory of Sustainable Chemical Transformation

Zitieren

APA

Bao, Z., Li, Q., Zhou, Z., Yang, J., & Zhang, L. (2025). Mitigating Uricase Immunogenicity through Zwitterionic Peptide Fusion for Enhanced Gout Therapy. Langmuir. https://doi.org/10.1021/acs.langmuir.5c00829

Vancouver

Bao Z, Li Q, Zhou Z, Yang J, Zhang L. Mitigating Uricase Immunogenicity through Zwitterionic Peptide Fusion for Enhanced Gout Therapy. Langmuir. 2025. doi:10.1021/acs.langmuir.5c00829

BibTeX
@article{Bao2025,
  author = {Bao, Zhun and Li, Qingsi and Zhou, Zhaoyu and Yang, Jing and Zhang, Lei},
  title = {Mitigating Uricase Immunogenicity through Zwitterionic Peptide Fusion for Enhanced Gout Therapy},
  journal = {Langmuir},
  year = {2025},
  doi = {10.1021/acs.langmuir.5c00829}
}
Kostenlos starten →